The potential of phytochemicals against epidermal growth factor receptor tyrosine kinase (EGFRK): an insight from molecular dynamic simulations

References

• Abdelgawad, M. A., Musa, A., Almalki, A. H., Alzarea, S. I., Mostafa, E. M., Hegazy, M. M., Mostafa-Hedeab, G., Ghoneim, M. M., Parambi, D. G. T., Bakr, R. B., Al-Muaikel, N. S., Alanazi, A. S., Alharbi, M., Ahmad, W., Bukhari, S. N. A., & Al-Sanea, M. M. (2021). Novel phenolic compounds as potential dual EGFR and COX-2 inhibitors: Design, semisynthesis, in vitro biological evaluation and in silico insights. Drug Design, Development and Therapy, 15, 2325–2337. https://doi.org/10.2147/DDDT.S310820
   PubMed Web of Science ®Google Scholar
• Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M., & Gouda, A. M. (2021). Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules (Basel, Switzerland), 26(21), 6677. https://doi.org/10.3390/molecules26216677
   PubMed Web of Science ®Google Scholar
• Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., & Fukami, Y. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinases. The Journal of Biological Chemistry, 262(12), 5592–5595. https://doi.org/10.1016/S0021-9258(18)45614-1
   PubMed Web of Science ®Google Scholar
• Arantes, P. R., Polêto, M. D., Pedebos, C., & Ligabue-Braun, R. (2021). Making it rain: Cloud-based molecular simulations for everyone. Journal of Chemical Information and Modeling, 61(10), 4852–4856. https://doi.org/10.1021/acs.jcim.1c00998
   PubMed Web of Science ®Google Scholar
• Arkin, M., & Moasser, M. M. (2008). HER-2-directed, small-molecule antagonists. Current Opinion in Investigational Drugs (London, England: 2000), 9(12), 1264–1276.
   PubMedGoogle Scholar
• Attique, S. A., Hassan, M., Usman, M., Atif, R. M., Mahboob, S., Al-Ghanim, K. A., Bilal, M., & Nawaz, M. Z. (2019). A molecular docking approach to evaluate the pharmacological properties of natural and synthetic treatment candidates for use against hypertension. International Journal of Environmental Research and Public Health, 16(6), 923. https://doi.org/10.3390/ijerph16060923
   PubMed Web of Science ®Google Scholar
• Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., Henthorn, L., & Richards, L. (2001). Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic & Medicinal Chemistry Letters, 11(14), 1911–1914. https://doi.org/10.1016/s0960-894x(01)00344-4
   PubMed Web of Science ®Google Scholar
• Bartholomew, C., Eastlake, L., Dunn, P., & Yiannakis, D. (2017). EGFR targeted therapy in lung cancer; an evolving story. Respiratory Medicine Case Reports, 20, 137–140. https://doi.org/10.1016/j.rmcr.2017.01.016
   PubMed Web of Science ®Google Scholar
• Benet, L. Z., Hosey, C. M., Ursu, O., & Oprea, T. I. (2016). BDDCS, the Rule of 5 and drugability. Advanced Drug Delivery Reviews, 101, 89–98. https://doi.org/10.1016/j.addr.2016.05.007
   PubMed Web of Science ®Google Scholar
• Berman, H., Henrick, K., & Nakamura, H. (2003). Announcing the worldwide Protein Data Bank. Nature Structural & Molecular Biology, 10(12), 980–980. https://doi.org/10.1038/nsb1203-980
   Web of Science ®Google Scholar
• Butti, R., Das, S., Gunasekaran, V. P., Yadav, A. S., Kumar, D., & Kundu, G. C. (2018). Receptor tyrosine kinases (RTKs) in breast cancer: Signaling, therapeutic implications and challenges. Molecular Cancer, 17(1), 34. https://doi.org/10.1186/s12943-018-0797-x
   PubMedGoogle Scholar
• Carpenter, G. (1987). Receptors for epidermal growth factor and other polypeptide mitogens. Annual Review of Biochemistry, 56, 881–914. https://doi.org/10.1146/annurev.bi.56.070187.004313
   PubMed Web of Science ®Google Scholar
• Chan, A. (2016). Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness. Therapeutic Advances in Medical Oncology, 8(5), 339–350. https://doi.org/10.1177/1758834016656494
   PubMed Web of Science ®Google Scholar
• Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., De Placido, S., Bianco, A. R., & Tortora, G. (2001). Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 7(5), 1459–1465.
   PubMed Web of Science ®Google Scholar
• Cohen, M. H., Johnson, J. R., Chen, Y. F., Sridhara, R., & Pazdur, R. (2005). FDA drug approval summary: Erlotinib (Tarceva) tablets. The Oncologist, 10(7), 461–466. https://doi.org/10.1634/theoncologist.10-7-461
   PubMed Web of Science ®Google Scholar
• Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., & Pazdur, R. (2003). FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. The Oncologist, 8(4), 303–306. https://doi.org/10.1634/theoncologist.8-4-303
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092. https://doi.org/10.1063/1.464397
   Web of Science ®Google Scholar
• Dubois, E. A., & Cohen, A. F. (2009). Panitumumab. British Journal of Clinical Pharmacology, 68(4), 482–483. https://doi.org/10.1111/j.1365-2125.2009.03492.x
   PubMed Web of Science ®Google Scholar
• Eastman, P., Swails, J., Chodera, J. D., McGibbon, R. T., Zhao, Y., Beauchamp, K. A., Wang, L. P., Simmonett, A. C., Harrigan, M. P., Stern, C. D., Wiewiora, R. P., Brooks, B. R., & Pande, V. S. (2017). OpenMM 7: Rapid development of high performance algorithms for molecular dynamics. PLoS Computational Biology, 13(7), e1005659. https://doi.org/10.1371/journal.pcbi.1005659
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49(21), 6177–6196. https://doi.org/10.1021/jm051256o
   PubMed Web of Science ®Google Scholar
• Gao, X., Le, X., & Costa, D. B. (2016). The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 16(4), 383–390. https://doi.org/10.1586/14737140.2016.1162103
   PubMed Web of Science ®Google Scholar
• Gao, Z., Wang, W., Gu, A., Lu, J., Huang, A., Xiong, L., Han, B., Jiang, L., & Shi, C. (2020). Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma. Translational Lung Cancer Research, 9(4), 1464–1471. https://doi.org/10.21037/tlcr-20-685
   PubMed Web of Science ®Google Scholar
• Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47(7), 1750–1759. https://doi.org/10.1021/jm030644s
   PubMed Web of Science ®Google Scholar
• Hirsh, V. (2011). Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Current Oncology (Toronto, ON), 18(3), 126–138. https://doi.org/10.3747/co.v18i3.877
   PubMed Web of Science ®Google Scholar
• Holbro, T., & Hynes, N. E. (2004). ErbB receptors: Directing key signaling networks throughout life. Annual Review of Pharmacology and Toxicology, 44, 195–217. https://doi.org/10.1146/annurev.pharmtox.44.101802.121440
   PubMed Web of Science ®Google Scholar
• Huang, C. Y., Chan, C. Y., Chou, I. T., Lien, C. H., Hung, H. C., & Lee, M. F. (2013). Quercetin induces growth arrest through activation of FOXO1 transcription factor in EGFR-overexpressing oral cancer cells. The Journal of Nutritional Biochemistry, 24(9), 1596–1603. https://doi.org/10.1016/j.jnutbio.2013.01.010
   PubMed Web of Science ®Google Scholar
• Ichimatsu, D., Nomura, M., Nakamura, S., Moritani, S., Yokogawa, K., Kobayashi, S., Nishioka, T., & Miyamoto, K. (2007). Structure-activity relationship of flavonoids for inhibition of epidermal growth factor-induced transformation of JB6 Cl 41 cells. Molecular Carcinogenesis, 46(6), 436–445. https://doi.org/10.1002/mc.20292
   PubMed Web of Science ®Google Scholar
• Jordan, J. D., Landau, E. M., & Iyengar, R. (2000). Signaling networks: The origins of cellular multitasking. Cell, 103(2), 193–200. https://doi.org/10.1016/s0092-8674(00)00112-4
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., O'Brien, S., Cortes, J., Giles, F. J., Rios, M. B., Shan, J., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Verstovsek, S., Wierda, W., Keating, M., & Talpaz, M. (2003). Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data. Cancer, 98(12), 2636–2642. https://doi.org/10.1002/cncr.11831
   PubMed Web of Science ®Google Scholar
• Kazandjian, D., Blumenthal, G. M., Yuan, W., He, K., Keegan, P., & Pazdur, R. (2016). FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 22(6), 1307–1312. https://doi.org/10.1158/1078-0432.CCR-15-2266
   PubMed Web of Science ®Google Scholar
• Kolibaba, K. S., & Druker, B. J. (1997). Protein tyrosine kinases and cancer. Biochimica et Biophysica Acta, 1333(3), F217–F248. https://doi.org/10.1016/S0304-419X(97)00022-X
   PubMed Web of Science ®Google Scholar
• Kozaki, K., Imoto, I., Pimkhaokham, A., Hasegawa, S., Tsuda, H., Omura, K., & Inazawa, J. (2006). PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Science, 97(12), 1351–1358. https://doi.org/10.1111/j.1349-7006.2006.00343.x
   PubMed Web of Science ®Google Scholar
• Kumamoto, T., Fujii, M., & Hou, D. X. (2009). Myricetin directly targets JAK1 to inhibit cell transformation. Cancer Letters, 275(1), 17–26. https://doi.org/10.1016/j.canlet.2008.09.027
   PubMed Web of Science ®Google Scholar
• Levitzki, A., & Gazit, A. (1995). Tyrosine kinase inhibition: An approach to drug development. Science (New York, NY), 267(5205), 1782–1788. https://doi.org/10.1126/science.7892601
   Google Scholar
• Li, J., Abel, R., Zhu, K., Cao, Y., Zhao, S., & Friesner, R. A. (2011). The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. Proteins, 79(10), 2794–2812. https://doi.org/10.1002/prot.23106
   PubMed Web of Science ®Google Scholar
• Lin, J., Zhang, S. M., Wu, K., Willett, W. C., Fuchs, C. S., & Giovannucci, E. (2006). Flavonoid intake and colorectal cancer risk in men and women. American Journal of Epidemiology, 164(7), 644–651. https://doi.org/10.1093/aje/kwj296
   PubMed Web of Science ®Google Scholar
• Lu, C., Wu, C., Ghoreishi, D., Chen, W., Wang, L., Damm, W., Ross, G. A., Dahlgren, M. K., Russell, E., Von Bargen, C. D., Abel, R., Friesner, R. A., & Harder, E. D. (2021). OPLS4: Improving force field accuracy on challenging regimes of chemical space. Journal of Chemical Theory and Computation, 17(7), 4291–4300. https://doi.org/10.1021/acs.jctc.1c00302
   PubMed Web of Science ®Google Scholar
• Mahmud, S., Paul, G. K., Biswas, S., Kazi, T., Mahbub, S., Mita, M. A., Afrose, S., Islam, A., Ahaduzzaman, S., Hasan, M. R., Shimu, M. S. S., Promi, M. M., Shehab, M. N., Rahman, E., Sujon, K. M., Alom, M. W., Modak, A., Zaman, S., Uddin, M. S., … Saleh, M. A. (2022). phytochemdb: A platform for virtual screening and computer-aided drug designing. Database, 2022(2022), baac002. https://doi.org/10.1093/database/baac002
   PubMedGoogle Scholar
• Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015). ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713. https://doi.org/10.1021/acs.jctc.5b00255
   PubMed Web of Science ®Google Scholar
• Mark, P., & Nilsson, L. (2001). Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. The Journal of Physical Chemistry A, 105(43), 9954–9960. https://doi.org/10.1021/jp003020w
   Web of Science ®Google Scholar
• Meng, X. Y., Zhang, H. X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7(2), 146–157. https://doi.org/10.2174/157340911795677602
   PubMed Web of Science ®Google Scholar
• Mitsudomi, T., & Yatabe, Y. (2010). Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. The FEBS Journal, 277(2), 301–308. https://doi.org/10.1111/j.1742-4658.2009.07448.x
   PubMed Web of Science ®Google Scholar
• Nami, B., Maadi, H., & Wang, Z. (2018). Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers, 10(10), 342. https://doi.org/10.3390/cancers10100342
   PubMed Web of Science ®Google Scholar
• Oda, K., Matsuoka, Y., Funahashi, A., & Kitano, H. (2005). A comprehensive pathway map of epidermal growth factor receptor signaling. Molecular Systems Biology, 1, 2005.0010. 2005.0010. https://doi.org/10.1038/msb4100014
   PubMed Web of Science ®Google Scholar
• Pagadala, N. S., Syed, K., & Tuszynski, J. (2017). Software for molecular docking: A review. Biophysical Reviews, 9(2), 91–102. https://doi.org/10.1007/s12551-016-0247-1
   PubMedGoogle Scholar
• Pawson, T. (1995). Protein modules and signalling networks. Nature, 373(6515), 573–580. https://doi.org/10.1038/373573a0
   PubMed Web of Science ®Google Scholar
• Plimpton, S. J., Pollock, R., & Stevens, M. J. (1997). Particle-Mesh Ewald and rRESPA for parallel molecular dynamics simulations [Paper presentation]. SIAM Conference on Parallel Processing for Scientific Computing.
   Google Scholar
• QikProp. (2021). Schrödinger release 2021-4. Schrödinger, LLC.
   Google Scholar
• Rewcastle, G. W., Palmer, B. D., Bridges, A. J., Showalter, H. D., Sun, L., Nelson, J., McMichael, A., Kraker, A. J., Fry, D. W., & Denny, W. A. (1996). Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 39(4), 918–928. https://doi.org/10.1021/jm950692f
   PubMed Web of Science ®Google Scholar
• Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27(3), 221–234. https://doi.org/10.1007/s10822-013-9644-8
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2022-2. (2021). LigPrep, S. L. N. Y. N. LigPrep.
   Google Scholar
• Schrödinger, LLC. (2021). Schrödinger release 2022-2: Prime. Schrödinger, LLC.
   Google Scholar
• Semsri, S., Seatew, C., Rattanabunyong, S., Ruekit, S., Horata, N., Panya, A., Yenchitsomanus, P. T., Sawatdichaikul, O., & Choowongkomon, K. (2020). In-vitro studies of anti-EGFR tyrosine kinase activity of Thai nutraceutical plants. Iranian Journal of Pharmaceutical Research: IJPR, 19(2), 199–206. https://doi.org/10.22037/ijpr.2017.2022
   PubMed Web of Science ®Google Scholar
• Shelley, J. C., Cholleti, A., Frye, L. L., Greenwood, J. R., Timlin, M. R., & Uchimaya, M. (2007). Epik: A software program for pK (a) prediction and protonation state generation for drug-like molecules. Journal of Computer-Aided Molecular Design, 21(12), 681–691. https://doi.org/10.1007/s10822-007-9133-z
   PubMed Web of Science ®Google Scholar
• Sorkin, A., & Goh, L. K. (2009). Endocytosis and intracellular trafficking of ErbBs. Experimental Cell Research, 315(4), 683–696. https://doi.org/10.1016/j.yexcr.2008.07.029
   PubMed Web of Science ®Google Scholar
• Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002). Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. The Journal of Biological Chemistry, 277(48), 46265–46272. https://doi.org/10.1074/jbc.M207135200
   PubMed Web of Science ®Google Scholar
• Suda, K., Onozato, R., Yatabe, Y., & Mitsudomi, T. (2009). EGFR T790M mutation: A double role in lung cancer cell survival? Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 4(1), 1–4. https://doi.org/10.1097/JTO.0b013e3181913c9f
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25(9), 1157–1174. https://doi.org/10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Weinstein, I. B. (2002). Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science (New York, N.Y.), 297(5578), 63–64. https://doi.org/10.1126/science.1073096
   PubMed Web of Science ®Google Scholar
• Wissner, A., Overbeek, E., Reich, M. F., Floyd, M. B., Johnson, B. D., Mamuya, N., Rosfjord, E. C., Discafani, C., Davis, R., Shi, X., Rabindran, S. K., Gruber, B. C., Ye, F., Hallett, W. A., Nilakantan, R., Shen, R., Wang, Y. F., Greenberger, L. M., & Tsou, H. R. (2003). Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). Journal of Medicinal Chemistry, 46(1), 49–63. https://doi.org/10.1021/jm020241c
   PubMed Web of Science ®Google Scholar
• Woodburn, J. R. (1999). The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology & Therapeutics, 82(2–3), 241–250. https://doi.org/10.1016/s0163-7258(98)00045-x
   PubMed Web of Science ®Google Scholar
• Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature reviews. Molecular cell biology, 2(2), 127–137. https://doi.org/10.1038/35052073
   Google Scholar
• Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013). Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(8), 2240–2247. https://doi.org/10.1158/1078-0432.CCR-12-2246
   PubMed Web of Science ®Google Scholar
• Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007). ErbB receptors: From oncogenes to targeted cancer therapies. The Journal of Clinical Investigation, 117(8), 2051–2058. https://doi.org/10.1172/JCI32278
   PubMed Web of Science ®Google Scholar